Leuphasyl Evidence Guide
Evidence for Leuphasyl is too preliminary to support a research protocol with confidence. No independent clinical data exists for this enkephalin-receptor analog in wrinkle reduction. All evidence is manufacturer-derived. Argireline has more independent evidence for the same cosmetic wrinkle-reduction application.
Our Take
Evidence for Leuphasyl is too preliminary to support a research protocol with confidence. No independent clinical data exists for this enkephalin-receptor analog in wrinkle reduction. All evidence is manufacturer-derived. Argireline has more independent evidence for the same cosmetic wrinkle-reduction application.
- Evidence context
- Opioid receptor modulation cosmetic research (manufacturer data only)
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established independent clinical protocol
Benefits and Evidence
- Expression Wrinkle Reduction: Level D, includes human evidence - Manufacturer data suggests modest wrinkle reduction after topical application, with enhanced effects when combined with Argireline (up to 47% wrinkle reduction in combination vs. 25% alone).
- Neurotransmitter Release Inhibition: Level D, mostly non-human evidence - In vitro studies on neuronal cell lines confirm reduced catecholamine release consistent with enkephalin-like activity.
Side Effects and Warnings
- Generally well tolerated topically
- Rare skin irritation
- No systemic opioid effects expected from topical application
- Limited independent clinical evidence
- Primarily supported by manufacturer data
- Efficacy depends on formulation and skin penetration
- Not a substitute for injectable neuromodulators
Research Dosage References
- <strong>Topical</strong> - 3-5% in formulation - Twice daily - Most effective in combination with Argireline (5-10%). Applied to areas with expression lines such as forehead and around eyes.
Mechanism of Action
Leuphasyl modulates neuromuscular activity through an opioid-receptor mechanism: 1. Enkephalin receptor binding: Binds to delta-opioid receptors on presynaptic nerve terminals at the neuromuscular junction. 2. Calcium channel modulation: Receptor activation inhibits voltage-gated calcium channels, reducing calcium influx into the nerve terminal. 3. Reduced neurotransmitter release: Lower intracellular calcium decreases acetylcholine vesicle fusion and release. 4. Complementary to Argireline: While Argireline targets the SNARE complex (post-calcium step), Leuphasyl acts upstream at the calcium entry step, providing a synergistic mechanism when combined.
Legal Status
Cosmetic ingredient. Available without prescription in skincare products. Not classified as a drug or controlled substance.
Primary Sources
- Pentapeptides as a neuropeptide approach to wrinkle reduction. International Journal of Cosmetic Science, 2005.
- Topical cosmeceutical peptides: a review of their efficacy. Journal of Drugs in Dermatology, 2009.
Quick Answers
Where is the strongest evidence for Leuphasyl?
Evidence for Leuphasyl is too preliminary to support a research protocol with confidence. No independent clinical data exists for this enkephalin-receptor analog in wrinkle reduction. All evidence is manufacturer-derived. Argireline has more independent evidence for the same cosmetic wrinkle-reduction application. Evidence context: Opioid receptor modulation cosmetic research (manufacturer data only).
What are the main side effects of Leuphasyl?
Leuphasyl side effects and warning signals include Generally well tolerated topically, Rare skin irritation, No systemic opioid effects expected from topical application, Limited independent clinical evidence, and Primarily supported by manufacturer data.
What evidence level is Leuphasyl?
Leuphasyl is rated Level D; the listed research status is Preclinical.